Loading clinical trials...
Loading clinical trials...
A Phase I, Dose Finding Study of the Combination of High-dose Statin Agent (Rosuvastatin) With Erlotinib in Patients With Advanced Solid Malignancies, With a Focus on Squamous Cell Carcinomas and NSCLC.
Conditions
Interventions
Erlotinib + Rosuvastatin
Locations
1
Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Start Date
March 1, 2009
Primary Completion Date
September 1, 2014
Completion Date
September 1, 2014
Last Updated
April 21, 2020
NCT07190248
NCT07042295
NCT06980038
NCT06305754
NCT05039801
NCT04929028
Lead Sponsor
Ottawa Hospital Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions